A-RAF Antibody (YA614)
(Synonyms: ARAF1, PKS, PKS2, ARAF, Serine/threonine-protein kinase A-Raf, Proto-oncogene A-Raf, Proto-oncogene A-Raf-1, Proto-oncogene Pks)Based on 1 Customer Validation
A-RAF Antibody (YA614) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to A-RAF.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, ICC/IF, IHC-P, FC
-
Reactivity :
Human, Mouse
-
Formulation:
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:50-1:200 | 1:50-1:200 | 1:50-1:100 |
Product Details
A-RAF Antibody (YA614) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to A-RAF.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Mouse
-
Observed Molecular WeightObserved band size: 68 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 68 kDa
Entrez Gene: 369 Human ; 11836 Mouse ; 64363 Rat
SwissProt: P10398 Human ; P04627 Mouse ; P14056 Rat
OMIM: 311010 Human
Synthetic peptide corresponding to Human A-RAF.AA range:146-310.
Endogenous
Protein A affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Western blot analysis of extracts from Hela (lane 2, 20ug), A549 (lane 3, 20ug), K562 (lane 4, 20ug) and NIH/3T3 (lane 5, 20ug) using A-RAF Antibody (HY-P80018). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.
-
Immunohistochemical analysis of paraffin-embedded human prostate cancer using A-RAF antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80018, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human prostate using A-RAF antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80018, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human thyroid using A-RAF antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80018, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human cervical cancer using A-RAF antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80018, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human tonsil using A-RAF antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80018, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human colon cancer using A-RAF antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80018, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Flow cytometric analysis of 1X106 HeLa cells labeling A-RAF Antibody(HY-P80018, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/100 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Rabbit IgG H&L (HY-P8002) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Rabbit IgG Isotype Control (HY-P80879, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Background
-
Function
A-Raf (ARAF) is a member of the RAF serine/threonine kinase family and functions as a downstream effector of RAS that initiates signaling through the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade, thereby regulating cellular growth, proliferation, and differentiation[1][2]. Mechanistically, activated A-Raf phosphorylates MEK1/2 and contributes to ERK activation, placing ARAF at a critical upstream position in MAPK pathway regulation[1][2]. Dysregulation of the RAS-RAF-MEK-ERK signaling network is strongly associated with oncogenesis, and recurrent activating alterations in ARAF have been identified in multiple cancer types, supporting its relevance in tumor biology and experimental cancer models[3][4]. Compared with the related RAF isoforms BRAF and CRAF, A-Raf displays distinct biochemical properties, including substantially lower kinase activity toward MEK and tighter regulatory control, which may contribute to isoform-specific signaling outputs and biological functions[3][2]. This distinction is particularly important because oncogenic activation mechanisms differ among RAF family members, and mutations equivalent to highly transforming BRAF variants do not necessarily produce the same biological effects in ARAF[2]. In disease models, ARAF dimerization has been shown to promote MAPK pathway activation and tumor cell invasion, highlighting its functional contribution beyond its comparatively weak catalytic activity[4]. For experimental and therapeutic applications, RAF inhibitors remain important tools for interrogating ARAF-dependent signaling; however, several type II RAF inhibitors exhibit reduced potency against A-Raf relative to other RAF isoforms, emphasizing the need to consider isoform selectivity when designing mechanistic studies or targeted therapeutic strategies[1][5].
-
Expression
Tissue_specificity:Mainly distributed in urogenital tissues -
Subunit
Interacts with TH1L/NELFD
-
SwissProt ID
-
Synonyms
ARAF1, PKS, PKS2, ARAF, Serine/threonine-protein kinase A-Raf, Proto-oncogene A-Raf, Proto-oncogene A-Raf-1, Proto-oncogene Pks
-
Research Field
Signal Transduction
Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)
References
[1]. Tkacik E, et al. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem. 2023 May;299(5):104634. [Content Brief]
[2]. Zhao J, et al. Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway. Int J Mol Sci. 2022 May 5;23(9):5158. [Content Brief]
[3]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
[4]. Mooz J, et al. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. Sci Signal. 2014 Aug 5;7(337):ra73. [Content Brief]
[5]. Ali SR, et al. Nerve Density and Neuronal Biomarkers in Cancer. Cancers (Basel). 2022 Oct 1;14(19):4817. [Content Brief]